Emergent BioSolutions Inc. (EBS) SEC Filings & Earnings Calls

CFO transition may cause temporary disruption in financial reporting and strategic planning.

“CFO departure with interim appointment; new CFO lacks prior CFO experience.”

Dependence on USG funding for MCM products.

“Availability of USG funding for contracts related to procurement of MCM products.”

Generic competition for naloxone products.

“Commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN.” · word for word

Debt covenants and liquidity risk.

“Ability to comply with operating and financial covenants required by term loan facility, revolving credit facility, and senior unsecured notes.”

Dependence on single government contract for revenue.

“Contract modification is under existing BARDA AV7909 contract.”

NARCAN pricing and volume decline

“changes in current and projected operating results, notably related to pricing and sales volumes for NARCAN®” · word for word

High debt and refinancing risk

“Total debt $ 589.7 million; loss on debt extinguishment $20.5 million”

Operating cash flow deterioration

“Net cash provided by operating activities $22.3 million vs $95.2 million prior year period”

Restructuring execution risk and potential business disruption

“charges consist primarily of cash charges related to severance, transition services, and estimated benefits cost” · word for word

Dependence on U.S. government contracts for revenue; contract modifications may not be repeated.

“This contract modification is under Emergent's existing 10-year contract with ASPR.” · word for word

Revenue concentration on US government contracts

“the availability of U.S. government (“USG”) funding for contracts related to procurement of our medical countermeasures (“MCM”) products” · word for word

Debt covenant compliance risk

“our ability to comply with the operating and financial covenants required by (i) the Credit Agreement, dated April 16, 2026” · word for word

Generic competition for NARCAN

“the commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN” · word for word

Revenue declined 30% YoY, though beat guidance; net income down 90% YoY.

“Total Revenues $156.1M vs $222.2M YoY (-30%); Net Income $6.8M vs $68.0M YoY (-90%).”

High interest rate (SOFR+6.25%) and prepayment premiums indicate elevated credit risk.

“Term Loan accrues interest at Term SOFR (floor 3.00%) plus 6.25% per annum; prepayment premiums up to make-whole plus 3%.”

Share Pool Constraint

“Due to a limited available share pool, the RSUs and PSUs were granted contingent upon stockholder approval of the amendment to the Plan to increase the number of shares available for grant.” · word for word

PSU Payout Discretion

“Although performance for the applicable PSU performance period did not reach the threshold level established at grant, the Compensation Committee exercised upward discretion to approve a 25% payout for all award recipients.” · word for word

Revenue Decline

“Total revenue was $742.9 million compared to $1,043.6 million in 2024” · word for word

Single-source supplier dependency

“We depend on certain single-source suppliers for key materials, API, excipients, components, devices, manufacturing and other services necessary to produce and release the majority of our products and certain product candidates.” · word for word

Litigation liability

“multiple purported class action lawsuits were filed against us... In February 2025, the Court granted final approval of a settlement” · word for word

Product liability exposure

“We face an inherent risk of product liability exposure related to the sale of our products” · word for word

Cybersecurity risk

“Our systems and those of our business partners and collaborators have in the past been, and in the future likely will be subject to computer viruses, malicious codes, unauthorized access and other cybersecurity incidents.” · word for word

Debt level

“Our level of indebtedness and the terms of our indebtedness could adversely affect our business and liquidity position.” · word for word

Revenue decline of 29% year-over-year; Q4 revenue down 24%

“Full Year 2025 Total Revenues of $742.9 million vs $1,043.6 million prior year; Q4 2025 Total Revenues of $148.7 million vs $194.7 million prior year” · word for word

Q4 net loss widened to $54.6M from $31.3M; adjusted net loss of $22.7M vs adjusted net income of $2.6M

“Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%; Adjusted Net Income (Loss) $ (22.7) million vs $2.6 million prior year” · word for word

Debt reduction reduces financial risk but transformation plan still ongoing

“multi-year transformation plan ... strong cash position for future strategic initiatives”

Revenue concentration and decline

“Total revenues decreased 21% YoY to $231.1M.”

Restructuring execution risk

“Restructuring costs of $0.3M in Q3 2025; cumulative restructuring charges from multiple plans.”

Revenue decline in core MCM products (anthrax, smallpox) and naloxone franchise due to timing and pricing pressures.

“Naloxone -21%; Anthrax MCM -88%; Smallpox MCM -37%.”

Dependence on government contracts and modifications for revenue visibility.

“Secured multiple contract modifications; international orders represent 34% of MCM orders YTD.”